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 INTRODUCTION
 In patients with infl ammatory bowel diseases (IBD), such as 
Crohn's disease (CD) and ulcerative colitis (UC), common symp-
toms include diarrhea, abdominal pain, or rectal bleeding ( 1–4 ). 
However, other gastrointestinal and psychosocial symptoms may 
be present, particularly when disease is active. Many of these addi-
tional symptoms impact patients physically and emotionally and 
have a negative impact on quality of life ( 5,6 ). Th ese symptoms 
are legitimate targets for treatments. Various symptom scales 
have been studied to assess the effi  cacy of IBD treatment ( 7–10 ). 
Th e Food and Drug Administration (FDA) has determined that 
for clinical trials of IBD treatments, co-primary endpoints of 
patient reported outcomes (PROs) and endoscopic endpoints are 
required. While candidate PRO measures have been proposed, a 
complete inventory of GI symptoms using validated PRO scales 
has not been available.
 IBD patients are reported to commonly have psychosocial 
symptoms such as depression and anxiety ( 11,12 ). Results of one 
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prospective cohort study suggest that depressive symptoms may 
increase the risk for CD among women ( 13 ). Additionally, depres-
sion has been shown to impact the course of IBD and is associated 
with worsened disease activity and complications ( 14 ). Further-
more, psychological symptoms can pose treatment barriers ( 15 ). 
However, there are no data to indicate how specifi c gastrointesti-
nal symptoms correlate with psychosocial symptoms in patients 
with IBD.
  PROs are important factors in understanding the burden of 
IBD. Th ere are a full range of GI symptoms that contribute to the 
burden of IBD. Th e National Institutes of Health’s Patient Reported 
Outcomes Measurement Information System (PROMIS) is a 
publically available, standardized set of PROs that cover physical, 
mental and social health. Recently, eight scales were developed 
for GI symptom domains under this framework ( 16 ). Th e re i s a  
greater need for the use of PROs to advance the understanding of 
symptoms in IBD patients. PROs can also be used both in clinical 
practice and in clinical trials as important endpoints. In this study, 
we aimed to determine whether GI-PROMIS domains can be used 
to assess symptoms in IBD patients.
    METHODS
   Study setting
 Th e Crohn’s and Colitis Foundation of America (CCFA) Partners 
study is a longitudinal Internet-based cohort of people living 
with IBD. Th e development of this cohort has been described in 
detail previously ( 17 ). In brief, we recruited participants with a 
self-reported diagnosis of CD, UC or indeterminate colitis (IC) 
who were 18 years of age or older through CCFA e-mail rosters, 
websites, various social media outlets, and at educational and 
fundraising events. To date, the cohort has enrolled over 15,000 
individuals with IBD. All participants completed a baseline sur-
vey including demographic information, questions about their 
IBD history, symptoms and medication use. Respondents then 
complete bi-annual surveys to update disease and demographic 
information. CCFA Partners surveys include a number of 
validated IBD activity indices, quality of life measures and 
PROMIS assessments as described below.
    Instruments
 Th e GI-PROMIS scales assess 8 domains: gastroesophageal refl ux 
(13 items), disrupted swallowing (7 items), diarrhea (5 items), 
bowel incontinence/soilage (4 items), nausea and vomiting 
(4 items), constipation (9 items), belly pain (6 items), and gas/
bloat/fl atulence (12 items) ( 16 ). All scales are reported in percen-
tiles, among individuals who report that symptom.
  Th e psychosocial PROMIS scales assess 6 domains: 
anxiety (4 items), depressive symptoms (4 items), fatigue (4 
items), pain interference (4 items), social satisfaction (4 
items) and sleep disturbance (4 items)( 18 ). All scales are 
calibrated using an item response theory graded response 
model and scored on a T-score metric with a mean of 50 and 
standard deviation (s.d.) of 10 in the US general population. A 
higher score denotes more symptoms on that scale, with the 
exception of social satisfaction, where a lower 
score indicates better social satisfaction. Based on prior data in 
chronic diseases, a minimally important diff erence (MID) for the 
psychosocial scales is 2–3 points ( 19 ).
 Disease activity instruments were also completed by participants 
at the time of the PROMIS scales. Subjects with CD completed the 
short Crohn's Disease Activity Index (sCDAI); on this scale, remis-
sion is defi ned as a score <150. Ulcerative colitis or indeterminate 
colitis subjects completed the Simple Clinical Colitis Activity Index 
(SCCAI); remission is defi ned as a score ≤2. Th e short Infl amma-
tory Bowel Disease Questionnaire (SIBDQ) is a measure of quality 
of life, a lower score indicates a worse quality of life.
 Study design
 We performed a cross-sectional analysis of IBD subjects enrolled 
in CCFA Partners from January 2015 to April 2016 who answered 
GI and psychosocial PROMIS domains. We stratifi ed subjects by 
factors such as surgical status, disease activity, and disease dura-
tion. We also assessed PROMIS domains by classes of medica-
tions.
 Statistical analysis
 We used descriptive statistics and bivariate analyses to evaluate 
GI-PROMIS measures relative to validated instruments such as 
the sCDAI, SCCAI and SIBDQ ( 20,21 ). We conducted a sensitiv-
ity analysis including only UC patients who have not undergone 
surgery. All analyses were performed in STATA 14.0 (College 
Station, TX). Th e study protocol was approved by the institutional 
review board at the University of North Carolina at Chapel Hill.
 RESULTS
 Demographics
 Th ere were 2,378 subjects with CD ( Table 1a ) and 1,455 subjects 
with UC ( Table 1b ; the IC patients were included with UC), who 
completed GI-PROMIS questionnaires. Respondents were pre-
dominantly female and white: 74% of CD and 72% of UC sub-
jects were female; 95% of CD subjects and 92% of UC subjects 
were white. A total of 72% of CD subjects and 77% of UC subjects 
reported a college degree or greater. Th e median age was 41 years 
for CD subjects (interquartile range (IQR): 29–54) and UC sub-
jects (IQR: 31–53). Median disease duration was 11 years (IQR: 
4–22) for CD subjects and 8 years (IQR: 3–15) for UC subjects. 
Most of the respondents had previously been hospitalized: 82% 
of CD subjects and 62% of UC subjects. Half of the CD subjects 
and 11% of UC subjects had previous surgery for IBD. At the time 
of the questionnaire, 57% of CD subjects and 42% of UC subjects 
were in remission.
 GI-PROMIS in subjects with Crohn's disease
 Among CD respondents, 24% reported refl ux, 9% reported dif-
fi culty swallowing, 52% reported diarrhea, 44% reported nausea 
and vomiting, 43% reported belly pain, 59% reported gas, 16% 
reported bowel incontinence and 15% reported constipation 
( Figure 1 ). Symptomatic CD subjects reported a higher level of 
symptoms than symptomatic subjects in the general population 
(54th percentile for diarrhea, 57th percentile for nausea and 
vomiting, 55th percentile for belly pain, 53rd percentile for gas, 
56th percentile for bowel incontinence and 53rd percentile for 
constipation;  Figure 2 ).
    GI-PROMIS in subjects with ulcerative colitis
  Among UC respondents, 9% reported refl ux, 3% reported diffi  -
culties swallowing, 17% reported diarrhea, 8% reported nausea 
and vomiting, 19% reported belly pain, 27% reported gas, 6% 
reported bowel incontinence and 7% reported constipation 
( Figure 1 ). Symptomatic UC subjects reported similar degrees 
of symptoms compared to symptomatic subjects in the general 
population (50th percentile for diarrhea, 49th percentile for belly 
pain and 48th percentile for constipation;  Figure 2 ). Similar 
trends were seen in a sub-group analysis of UC subjects who did 
not have surgery.
    Differences by surgical status
  Compared to CD subjects who did not have prior surgery for CD, 
those who had surgery reported more diarrhea ( P <0.01), belly 
pain ( P =0.02), gas ( P =0.04) and bowel incontinence ( P <0.01). 
Th ere were no meaningful diff erences between UC subjects based 
on surgical status.
 Differences by disease activity, quality of life and psychosocial 
measures
 Among symptomatic CD subjects, those with active disease 
reported signifi cantly more symptoms on all 8 GI-PROMIS 
domains than those in remission ( Table 2a ). With the exception 
of disrupted swallowing, symptomatic UC subjects with active 
disease also reported signifi cantly more symptoms on the other 7 
GI-PROMIS than UC subjects in remission ( Table 2b ).
 When stratifi ed by quartiles of the SIBDQ, symptomatic CD and 
UC subjects in the lowest quartile (worst quality of life) reported 
signifi cantly more symptoms on all 8 GI-PROMIS domains com-
pared to those in the highest quartile (best quality of life). Th ere 
was a trend toward decreasing GI symptoms with higher SIBDQ 
scores ( Table 3 ).
 Respondents who reported more symptoms on the GI-PROMIS 
domains reported signifi cantly more symptoms on the psycho-
social PROMIS domains. We present data from three representa-
tive domains, diarrhea, belly pain and gas. Amongst CD subjects, 
 Table 1a .  Characteristics of the population with Crohn's disease 
 Characteristic  Crohn's disease, ( n =2,378) 
% or median (IQR) 
 % Female  74 
 Age (years)  41 (29–54) 
 Race 
 % White  95 
 % Black  1 
 % College graduate or greater  72 
 Body mass index (BMI)  24 (22–29) 
 % Current smokers  7 
 Disease duration (years)  11 (4–22) 
 % Currently used medications 
 Corticosteroids  13 
 Mesalamine agents  26 
 Immunomodulators  29 
 Anti-TNF Biologicals  49 
 Probiotics  26 
 Antibiotics  4 
 Narcotics  12 
 % With a prior IBD hospitalization  82 
 % With prior IBD surgery  50 
 Disease activity (% remission a )  57 
 SIBDQ  5.0 (3.9–5.8) 
 IBD, infl ammatory bowel diseases; IQR, interquartile range; SIBDQ, short infl am-
matory bowel disease questionnaire; TNF, tumor necrosis factor. 
 a Defi ned as a short Crohn’s disease activity index (sCDAI) <150. 
 Table 1b .  Characteristics of the population with ulcerative colitis 
 Characteristic  Ulcerative colitis, ( n =1455) 
% of median (IQR) 
 % Female  72 
 Age (years)  41 (31–53) 
 Race 
 % White  92 
 % Black  1 
 % College graduate or greater  77 
 Body mass index (BMI)  25 (22–29) 
 % Current smokers  3 
 Disease Duration (years)  8 (3–15) 
 % Currently Used Medications 
 Corticosteroids  13 
 Mesalamine agents  59 
 Immunomodulators  22 
 Anti-TNF Biologicals  26 
 Probiotics  31 
 Antibiotics  3 
 Narcotics  6 
 % With a prior IBD hospitalization  62 
 % With prior IBD surgery  11 
 Disease activity (% remission a )  42 
 SIBDQ  5.2 (4.1–5.9) 
 IBD, infl ammatory bowel diseases; IQR, interquartile range; SIBDQ, short infl am-
matory bowel disease questionnaire; TNF, tumor necrosis factor. 
 a Defi ned as a Simple Clinical Colitis Activity Index (SCCAI) <2. 
in general, those who had more GI symptoms reported signifi 
-cantly more psychosocial symptoms than those who had less 
GI symptoms compared to those who did not report any GI 
symp-
toms ( Table 4a ). In the UC cohort, those who had more GI symp-
toms reported signifi cantly more psychosocial symptoms than 





















































































































































 Figure 2 .  Gastrointestinal Patient Reported Outcome Measurement Information System (GI-PROMIS) symptom scales in symptomatic subjects with infl am-
matory bowel disease (domains are reported as percentiles compared to all those in the general population who reported that symptom).
 Table 2a .  Gastrointestinal Patient Reported Outcome 
Measurement Information System (GI-PROMIS) domain 
percentiles stratifi ed by remission status for symptomatic subjects 
with Crohn's disease 
 Active disease 
( n =1,023) 
 Remission 
( n =1,355) 
 P -value 
 Refl ux  63 44  <0.01 
 Swallowing 59 46  <0.01 
 Diarrhea 67 40  <0.01 
 Nausea and vomiting  63 42  <0.01 
 Belly pain  68 37  <0.01 
 Gas/bloat/fl atulence  67 42  <0.01 
 Bowel incontinence  63 44  <0.01 
 Constipation 64 48  <0.01 
 Remission in Crohn's disease defi ned as a short Crohn's Disease Activity Index 
(sCDAI) <150. 
 Table 2b .  Gastrointestinal Patient Reported Outcome 
Measurement Information System (GI-PROMIS) domain 
percentiles stratifi ed by remission status for symptomatic 
subjects with ulcerative colitis 
 Active disease 
( n =844) 
 Remission 
( n =611) 
 P -value 
 Refl ux  50 36  <0.01 
 Swallowing  51 39 0.09 
 Diarrhea 58 26  <0.01 
 Nausea and vomiting  52 37  <0.01 
 Belly pain  55 33  <0.01 
 Gas/bloat/fl atulence  55 39  <0.01 
 Bowel incontinence  54 29  <0.01 
 Constipation 56 36  <0.01 
 Remission in ulcerative colitis defi ned as Short Clinical Colitis Activity Index 
(SCCAI) <2. 
IBD. Within the IBD population, there were strong associations 
between worsened GI symptoms and worsened quality of life, dis-
ease activity and psychosocial symptoms.
 Th ere have been few studies comparing the prevalence of gastro-
intestinal symptoms in IBD subjects to those of the general popu-
lation ( 23,24 ). We found that symptomatic IBD subjects report GI 
symptoms in the same range as the general population who report 
these symptoms. In essence, regardless of the cause of the symp-
tom (such as diarrhea), subjects with IBD and those without IBD 
report a similar symptom burden. Th ere were no notable diff er-
ences when stratifi ed by age, gender or disease duration. It is pos-
sible that IBD subjects are accustomed to GI symptoms and have 
been able to accommodate over time. Th is fi nding may also refl ect 
disease control. A sub-group analysis confi rmed that those who 
had active disease reported worsened GI symptoms when com-
pared to those in remission, with the exception of disrupted swal-
lowing in UC subjects. Th ese fi ndings are in line with a prior study 
demonstrating a high symptom burden in IBD patients. Th is study 
also demonstrated that while many patients with inactive disease 
report GI symptoms, the symptoms burden was highest amongst 
patients with active IBD ( 25 ).
symptoms reported psychosocial symptoms in the same range as 
those who did not have any GI symptoms ( Table 4b ).
    Differences by narcotic use
S  ymptomatic CD subjects on narcotics reported signifi cantly 
more symptoms on all 8 GI-PROMIS domains compared to those 
not on narcotics. Symptomatic UC subjects on narcotics reported 
more refl ux (68th percentile vs. 45th percentile,  P <0.01), diarrhea 
(71st percentile vs. 48th percentile,  P <0.01), nausea and vomit-
ing (66th percentile vs. 48th percentile,  P <0.01), belly pain (65th 
percentile vs. 47th percentile,  P <0.01) and gas (69th percentile vs. 
47th percentile,  P <0.01) compared to those not on narcotics.
     DISCUSSION
  Patient reported outcomes (PROs) are an essential 
component of patient centered research. Th e GI-PROMIS 
scales are a recent addition to the PROMIS portfolio that are 
freely available to the public free of charge, low burden for 
patients to complete and capable of implementation in 
clinical practice ( 22 ). We present data on GI-PROMIS scales 
in a large cohort of subjects with  
 Table 3 .  Gastrointestinal Patient Reported Outcome Measurement Information System (GI-PROMIS) percentiles in symptomatic 
infl ammatory bowel disease subjects stratifi ed by quartiles of the Short Infl ammatory Bowel Disease Questionnaire (SIBDQ) 
 GI-PROMIS domain percentiles 
 Crohn's disease 
 SIBDQ quartile 1 
(1–2.9,  n =551) 
 SIBDQ quartile 2 
(4–5,  n =612) 
 SIBDQ quartile 3 
(5.1–5.8,  n =566) 
 SIBDQ quartile 4 
(5.9–7,  n =642) 
 P -value 
 Refl ux  69  52  48  33  <0.01 
 Disrupted swallowing  70  49  38  41  <0.01 
 Diarrhea  77  59  44  28  <0.01 
 Nausea and vomiting  72  53  45  30  <0.01 
 Belly pain  80  56  40  28  <0.01 
 Gas/bloat/fl atulence  76  61  47  30  <0.01 
 Bowel incontinence  68  56  49  36  <0.01 
 Constipation  69  57  45  40  <0.01 
 Ulcerative colitis 
 SIBDQ quartile 1 
(1–4.1,  n =319) 
 SIBDQ quartile 2 
(4.2–5.2,  n =398) 
 SIBDQ quartile 3 
(5.3–5.9,  n =336) 
 SIBDQ quartile 4 
(6–7,  n =394) 
 P -value 
 Refl ux  61 55 34 32  <0.01 
 Disrupted swallowing  65  50  40  25  <0.01 
 Diarrhea 77  50  36  24  <0.01 
 Nausea and vomiting  61  49  44  25  <0.01 
 Belly pain  73  50  35  26  <0.01 
 Gas/bloat/fl atulence  73  54  40  30  <0.01 
 Bowel incontinence  63  50  42  33  <0.01 
 Constipation 72  49  39  32  <0.01 
 GI-PROMIS percentiles cannot be calculated in persons not experiencing a given symptom. 
I  t is notable that IBD subjects report levels of gastrointesti-
nal symptoms similar to the general population in all domains, 
including those not traditionally associated with IBD, such as 
refl u x and d isrupted s wallowing. Prior research h as s hown t hat 
people with medically unexplained symptoms, such as an ulcera-
tive colitis patient who has refl u x or a  C rohn's p atient w ho h as 
disrupted swallowing, report more symptoms when recalling a 
7 day period compared to people who do not have as many medically 
unexplained symptoms ( 26 ). It is possible that poorly controlled 
IBD may result in a variety of previously unrecognized symptoms 
due to a lack of awareness from patients and providers alike. It 
is also possible that individuals with IBD have a perception of 
poor overall gastrointestinal health, thus reporting symptoms in 
all categories.
 Prior studies have shown the association between depression/
anxiety and treatment adherence, worsening symptoms of IBD 
and general social functioning ( 6,15,27,28 ). We demonstrate that 
those subjects with worsened GI symptoms on the PROMIS scales 
also report worsened psychosocial symptoms, namely depression, 
anxiety, pain interference, fatigue, social satisfaction and sleep 
disturbance. For both CD and UC subjects, minimal levels of GI 
symptoms did not increase psychosocial symptoms when com-
pared to those without GI symptoms. However, those who have 
high levels of GI symptoms report psychosocial symptoms that 
are meaningfully higher than reference populations. In summary, 
those with well controlled GI symptoms are similar to those who 
are asymptomatic, but those with poorly controlled GI symptoms 
have worsened psychosocial symptoms.
 Table 4a .  Association between gastrointestinal symptoms and 
psychosocial Patient Reported Outcome Measurement Information 
System (PROMIS) domains in Crohn’s disease 
 Psychosocial PROMIS 
Domains 
 GI-PROMIS Domain 
 No diarrhea 
( n =578) 
 Low diarrhea 
( n =569) 
 High diarrhea 
( n =536) 
 Anxiety 50  50 57 
 Depressive symptoms  48  49  55 
 Fatigue  51  54  62 
 Pain interference  48  50  58 
 Sleep disturbance  52  52  52 
 Social Satisfaction  52  51  43 
 No belly pain 
( n =748) 
 Low belly 
pain ( n =465) 
 High belly 
pain ( n =460) 
 Anxiety  49  52  58 
 Depressive symptoms  48  50  56 
 Fatigue  50  55  64 
 Sleep disturbance  52  52  52 
 Social satisfaction  53  50  42 
 No gas 
( n =380) 
 Low gas 
( n =647) 
 High gas 
( n =635) 
 Anxiety 50  50 56 
 Depressive symptoms  48  48  55 
 Fatigue  51  52  61 
 Pain interference  49  48  57 
 Sleep disturbance  52  52  52 
 Social satisfaction  52  52  45 
 The numbers in the table are T scores. The psychosocial PROMIS domains are 
scored on a T-score metric with a mean of 50 and standard deviation (s.d.) of 10 
in the United States general population. A higher score denotes more symptoms 
on that scale, with the exception of social satisfaction, where a lower score 
indicates better social satisfaction. A minimally important difference (MID) for the 
psychosocial scales is 2–3. 
 Low and high gastrointestinal (GI) symptoms divided at the median reported on 
the GI-PROMIS scales. 
 Table 4b .  Association between gastrointestinal symptoms 
and psychosocial Patient Reported Outcome Measurement 
Information System (PROMIS) domains in ulcerative colitis 
 Psychosocial PROMIS 
Domains 
 GI-PROMIS domain 
 No diarrhea 
( n =533) 
 Low diarrhea 
( n =274) 
 High diarrhea 
( n =206) 
 Anxiety 50 51  57 
 Depressive symptoms  48 49 55 
 Fatigue 51 53 60 
 Pain interference  48 50 58 
 Sleep disturbance  52 52 52 
 Social Satisfaction  53 51 43 
 No belly pain 
( n =475) 
 Low belly 
pain ( n =322) 
 High belly 
pain ( n =212) 
 Anxiety 49 53 57 
 Depressive symptoms  48 50 55 
 Fatigue 49 53 61 
 Sleep disturbance  52 52 52 
 Social satisfaction  54 50 43 
 No gas 
( n =251) 
 Low gas 
( n =431) 
 High gas 
( n =317) 
 Anxiety 49  50  56 
 Depressive symptoms  47 48  54 
 Fatigue 50 51 59 
 Pain interference  48 48 55 
 Sleep disturbance  52 52 52 
 Social satisfaction  53 52 46 
 The numbers in the table are T scores. The psychosocial PROMIS domains are 
scored on a T-score metric with a mean of 50 and standard deviation (s.d.) of 10 
in the United States general population. A higher score denotes more symptoms 
on that scale, with the exception of social satisfaction, where a lower score 
indicates better social satisfaction. A minimally important difference (MID) for 
the psychosocial scales is 2–3. 
 Low and high gastrointestinal (GI) symptoms divided at the median reported on 
the GI-PROMIS scales. 
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE 
 ✓  Infl ammatory bowel diseases (IBD) subjects frequently
report diarrhea and abdominal pain.
 ✓  IBD subjects have increased depression and anxiety.
 ✓  Patient reported outcomes (PROs) are important factors in
understanding the burden of IBD.
 WHAT IS NEW HERE 
 ✓  Gastrointestinal (GI) symptoms, such as refl ux and disrupted
swallowing, are also commonly reported in IBD.
 ✓  Among IBD subjects experiencing GI symptoms, worsened
GI symptoms correlate with worsened depression and
anxiety.
 ✓  Among IBD subjects experiencing GI symptoms, narcotic
use and corticosteroid use are associated with worsened GI
symptoms.
 ✓  GI-PROMIS (Gastrointestinal PRO measurement informa-
tion system) scales correlate with other validated measures
of disease activity and quality of life in IBD.
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  In a sub-group analyses by SIBDQ and disease activity indices, 
those subjects who reported worsened quality of life and disease 
activity also reported worsened GI symptoms for all eight 
GI-PROMIS scales. Th i s s upports t he f act t hat t he P ROMIS 
scales are good measures of GI symptoms in IBD subjects and are 
responsive to diff erences in disease activity. However, it should be 
noted that these disease activity measures include symptoms and 
therefore, it is not surprising that they do correlate so well.
  While there are data on the harmful eff e cts o f n arcotics i n 
patients with IBD ( 29,30 ), there are no specifi c  reports correlat-
ing narcotics with worsening GI symptoms, as we demonstrate. It 
is possible that use of narcotics is a marker of poorly controlled 
IBD ( 31 ), explaining the presence of worsened GI symptoms. It 
is also possible that use of narcotics is a marker for poorly con-
trolled symptoms of irritable bowel syndrome (IBS), which can be 
prevalent in IBD patients ( 24,32 ). Finally, it is possible that nar-
cotics themselves could paradoxically worsen various GI symptom 
measures, perhaps through mechanisms of alternation of motility.
 Th ere are several strengths of this study, including the large sam-
ple size and geographically diverse population. However, there are 
limitations as well. Primarily, this is a cross-sectional study, which 
precludes the ability to determine causality. Th e demographics of 
the population, predominantly female, white and well-educated, 
does not refl ect the IBD population across the US. Th er efore, th e 
CCFA-Partners Internet-based cohort is not representative of 
the US IBD population. Th is cohort focuses on patient reported 
information without individualized confi rmation from a medical 
record. However, a validation study from a subset of this cohort 
revealed 97% concordance between self-reported diagnosis of 
IBD and evaluation of the medical record ( 33 ). In addition, the 
self-reported data collection should not aff ect the reliability of the 
responses for the PROMIS scales.
  In conclusion, this cross-sectional analysis is the fi rst report of 
the previously validated GI-PROMIS scales in a large sample of 
IBD subjects. Th ese measures were found to correlate with other 
validated scales of quality of life and disease activity. Furthermore, 
higher percentiles on a GI-PROMIS domains correlate with worse 
psychosocial PROs in this IBD population. GI-PROMIS domains 
hold potential as important PRO measures in IBD subjects. Th i s 
is especially important as there is a need for improved treatment 
endpoints in clinical IBD management and in IBD clinical trials.
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